ID   HCC1143 BL
AC   CVCL_1246
SY   HCC-1143BL; HCC1143-BL; HCC1143BL; Hamon Cancer Center 1143 BL
DR   CLO; CLO_0003631
DR   ATCC; CRL-2362
DR   BioSample; SAMN03471830
DR   cancercelllines; CVCL_1246
DR   Cell_Model_Passport; SIDM00868
DR   dbGAP; phs001839.v1.p1
DR   DepMap; ACH-002378
DR   DSMZ; ACC-893
DR   DSMZCellDive; ACC-893
DR   GEO; GSM854620
DR   GEO; GSM1172955
DR   PharmacoDB; HCC1143BL_467_2019
DR   Progenetix; CVCL_1246
DR   Wikidata; Q54881531
RX   PubMed=9833771;
RX   PubMed=20164919;
RX   PubMed=24176112;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Doubling time: ~40-50 hours (DSMZ=ACC-893).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Deep exome analysis.
CC   Omics: Genome sequenced.
CC   Omics: SNP array analysis.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
ST   Source(s): ATCC; DSMZ
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 12,13
ST   D16S539: 11,13
ST   D18S51: 14,17
ST   D19S433: 13,17
ST   D21S11: 30.2,31
ST   D2S1338: 20,23
ST   D3S1358: 14,16
ST   D5S818: 11
ST   D7S820: 10,12
ST   D8S1179: 13
ST   FGA: 20,21
ST   Penta D: 8,12
ST   Penta E: 10
ST   TH01: 9.3
ST   TPOX: 10,12
ST   vWA: 16,20
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_1245 ! HCC1143
SX   Female
AG   52Y
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 26
//
RX   PubMed=9833771; DOI=10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L;
RA   Gazdar A.F., Kurvari V., Virmani A.K., Gollahon L., Sakaguchi M.,
RA   Westerfield M., Kodagoda D.R., Stasny V., Cunningham H.T., Wistuba I.I.,
RA   Tomlinson G.E., Tonk V., Ashfaq R., Leitch A.M., Minna J.D., Shay J.W.;
RT   "Characterization of paired tumor and non-tumor cell lines established
RT   from patients with breast cancer.";
RL   Int. J. Cancer 78:766-774(1998).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//